Pacira BioSciences Analyst Price Targets

Wall Street analyst price targets and consensus rating for Pacira BioSciences (PCRX).

Price Target Range — 12 Quarters

Analyst Consensus — 11 Analysts

4Buy

7Hold

Consensus RatingOutperform# Analysts11Avg. Consensus PT$36Upside to Avg. PT-0.9%

Rating Trend — Last 9 Months

Recent Analyst Actions

Visualizza tutte le valutazioni →

Date	Firm	Analyst	Action	Rating Change	Price Target
Oct 9, 2026	Truist Securities	Anish Nikhanj	Downgrade	Buy→Hold	$31→$37
Oct 9, 2026	RBC Capital	Douglas Miehm	PT Raise	Sector Perform	$25→$37
Oct 9, 2026	HC Wainwright & Co.	Douglas Tsao	Downgrade	Buy→Neutral	$38→$37
Oct 8, 2026	JP Morgan	Hardik Parikh	Upgrade	Underweight→Neutral	$37
Oct 8, 2026	Jefferies	Glen Santangelo	Downgrade	Buy→Hold	$36
Oct 8, 2026	Needham	Serge Belanger	Downgrade	Buy→Hold	—
Oct 7, 2026	Truist Securities	Les Sulewski	PT Raise	Buy	$30→$31
Sep 23, 2026	Oppenheimer	Les Sulewski	Initiate	Outperform	$32
Sep 9, 2026	Leerink Partners	Daniel Clark	Initiate	Market Perform	$28
Aug 5, 2026	RBC Capital	Douglas Miehm	PT Raise	Sector Perform	$24→$25
Aug 5, 2026	Needham	Serge Belanger	PT Raise	Buy	$32→$33
Jul 1, 2026	HC Wainwright & Co.	Douglas Tsao	Maintained	Buy	$38
May 1, 2026	RBC Capital	Douglas Miehm	PT Raise	Sector Perform	$22→$24
May 1, 2026	Needham	Serge Belanger	PT Raise	Buy	$30→$32
Mar 26, 2026	Barclays	Glen Santangelo	PT Cut	Equal-Weight	$27→$25
Jan 9, 2026	HC Wainwright & Co.	Douglas Tsao	Maintained	Buy	$38
Jan 9, 2026	Needham	Serge Belanger	Maintained	Buy	$30
Dec 9, 2025	Barclays	Glen Santangelo	Initiate	Equal-Weight	$27
Nov 17, 2025	HC Wainwright & Co.	Douglas Tsao	Assumes	Buy	$38
Nov 7, 2025	Truist Securities	Les Sulewski	PT Cut	Buy	$30→$28

Analyst Ratings News

PRO
Truist Securities Downgrades Pacira BioSciences to Hold, Raises Price Target to $36.5

Truist Securities analyst Anish Nikhanj downgrades Pacira BioSciences (NASDAQ:PCRX) from Buy to Hold and raises the price target from $31 to $36.5.

Benzinga Newsdesk

PRO
RBC Capital Maintains Sector Perform on Pacira BioSciences, Raises Price Target to $36.5

RBC Capital analyst Douglas Miehm maintains Pacira BioSciences (NASDAQ:PCRX) with a Sector Perform and raises the price target from $25 to $36.5.

Benzinga Newsdesk

This Voya Financial Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Friday

Analysts downgraded Voya, Pacira, Genworth, and more, with price-target changes for several.

Avi Kapoor

CrowdStrike To Rally Around 18%? Here Are 10 Top Analyst Forecasts For Friday

Analysts raised targets for HOOD, SAIL, U and CRWD; cut targets for BULL, ALGN and PCRX, with PCRX downgraded to Neutral.

Avi Kapoor

PRO
HC Wainwright & Co. Downgrades Pacira BioSciences to Neutral, Lowers Price Target to $36.5

HC Wainwright & Co. analyst Douglas Tsao downgrades Pacira BioSciences (NASDAQ:PCRX) from Buy to Neutral and lowers the price target from $38 to $36.5.

Benzinga Newsdesk

PRO
Jefferies Downgrades Pacira BioSciences to Hold, Announces $36 Price Target

Jefferies analyst Glen Santangelo downgrades Pacira BioSciences (NASDAQ:PCRX) from Buy to Hold and announces $36 price target.

Benzinga Newsdesk

Pacira BioSciences Inc

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO

Pacira BioSciences Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PRO
Truist Securities Downgrades Pacira BioSciences to Hold, Raises Price Target to $36.5

PRO
RBC Capital Maintains Sector Perform on Pacira BioSciences, Raises Price Target to $36.5

This Voya Financial Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Friday

CrowdStrike To Rally Around 18%? Here Are 10 Top Analyst Forecasts For Friday

PRO
HC Wainwright & Co. Downgrades Pacira BioSciences to Neutral, Lowers Price Target to $36.5

PRO
Jefferies Downgrades Pacira BioSciences to Hold, Announces $36 Price Target

People Also Watch

People Also Watch

Pacira BioSciences Inc

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO

Pacira BioSciences Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PROTruist Securities Downgrades Pacira BioSciences to Hold, Raises Price Target to $36.5

PRORBC Capital Maintains Sector Perform on Pacira BioSciences, Raises Price Target to $36.5

This Voya Financial Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Friday

CrowdStrike To Rally Around 18%? Here Are 10 Top Analyst Forecasts For Friday

PROHC Wainwright & Co. Downgrades Pacira BioSciences to Neutral, Lowers Price Target to $36.5

PROJefferies Downgrades Pacira BioSciences to Hold, Announces $36 Price Target

People Also Watch

People Also Watch

PRO
Truist Securities Downgrades Pacira BioSciences to Hold, Raises Price Target to $36.5

PRO
RBC Capital Maintains Sector Perform on Pacira BioSciences, Raises Price Target to $36.5

PRO
HC Wainwright & Co. Downgrades Pacira BioSciences to Neutral, Lowers Price Target to $36.5

PRO
Jefferies Downgrades Pacira BioSciences to Hold, Announces $36 Price Target